Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients

Antiviral Therapy

Volumn 15, Issue 8, 2010, Pages 1171-1178

  Yang, Jing Xian ^a   Liu, Bao Ming ^a   Li, Xiao Guang ^b   Yan, Chun Hui ^a   Xu, Jie ^b   Sun, Xie Wen ^c   Wang, Yu Hua ^c   Jiao, Xiu Juan ^c   Yan, Ling ^a   Dong, Jian Ping ^d   Hou, Chun Sheng ^e   Abuduheilili, Xiernayi ^f   Li, Tong ^a   Zhuang, Hui ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b PEKING UNIVERSITY THIRD HOSPITAL   (China)

^c Qinhuangdao Third Hospital   (China)

^d Beijing Haidian Hospital   (China)

^e JINAN INFECTIOUS DISEASE HOSPITAL   (China)

^f XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; ENTECAVIR; LAMIVUDINE; RNA DIRECTED DNA POLYMERASE; TELBIVUDINE;

ADD ON THERAPY; ADULT; AGED; ANTIVIRAL RESISTANCE; ARTICLE; CHINESE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE SEQUENCE; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MOLECULAR EVOLUTION; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; VIRUS GENE; VIRUS MUTATION;

ADENINE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CHINA; CROSS-SECTIONAL STUDIES; DNA, VIRAL; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; FEMALE; GUANINE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MOLECULAR TYPING; MUTATION, MISSENSE; NUCLEOSIDES; PHOSPHONIC ACIDS; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; YOUNG ADULT;

EID: 78650972867     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1677     Document Type: Article

References (33)

1. Leung NW, Lai CL, Chang TT, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33:1527-1532.
2. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003; 348:808-816. (Pubitemid 36245757)
3. Lok AS, Zoulim F, Locarnini S, et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 2007; 46:254-265.
4. Locarnini S, Mason WS. Cellular and virological mechanisms of HBV drug resistance. J Hepatol 2006; 44:422-431. (Pubitemid 43069226)
5. Chinese Society of Hepatology, Chinese Medical Association and Chinese Society of Infectious Diseases, Chinese Medical Association. Guideline on prevention and treatment of chronic hepatitis B in China. Chin Med J (Engl) 2007; 120:2159-2173.
6. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50:661-662.
7. Lok AS. Evolution of nucleoside/tide analogues for hepatitis B: is the ideal drug here yet? J Hepatol 2009; 51:416-418.
8. Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359:2442-2455.
9. Locarnini S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008; 2:147-151.
10. Stuyver LJ, Locarnini SA, Lok A, et al. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 2001; 33:751-757.
11. Borroto-Esoda K, Miller MD, Arterburn S. Pooled analysis of amino acid changes in the HBV polymerase in patients from four major adefovir dipivoxil clinical trials. J Hepatol 2007; 47:492-498.
12. Liu BM, Li T, Xu J, et al. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment naïve Chinese patients. Antiviral Res 2010; 85:512-519.
13. Zoulim F. Detection of hepatitis B virus resistance to antivirals. J Clin Virol 2001; 21:243-253.
14. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006; 44:593-606. (Pubitemid 43227885)
15. Langley DR, Walsh AW, Baldick CJ, et al. Inhibition of hepatitis B virus polymerase by entecavir. J Virol 2007; 81:3992-4001.
16. Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129:528-536. (Pubitemid 41096641)
17. Zoulim F, Durantel D, Deny P. Management and prevention of drug resistance in chronic hepatitis B. Liver Int 2009; 29:108-115.
18. Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol 2008; 48:747-755.
19. Ciancio A, Smedile A, Rizzetto M, Lagget M, Gerin J, Korba B. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology 2004; 39:64-73. (Pubitemid 38461468)
20. Svicher V, Gori C, Trignetti M, et al. The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes. J Hepatol 2009; 50:461-470.
21. de Franchis R, Hadengue A, Lau G, et al. EASL International Consensus Conference on Hepatitis B. 13-14 September 2002, Geneva, Switzerland. J Hepatol 2003; 39 Suppl 1:S3-S25.
22. HIV-Grade. Tool for analysis of HBV resistance. (Accessed 1 May 2010.) Available from http://www.hiv-grade.de/cms/grade/hbv-tool.html
23. Liu Y, Wang CM, Cheng J, et al. Hepatitis B virus in tenofovir-naive Chinese patients with chronic hepatitis B contains no mutation of rtA194T conferring a reduced tenofovir susceptibility. Chin Med J (Engl) 2009; 122:1585-1586.
24. Baldick CJ, Tenney DJ, Mazzucco CE, et al. Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 2008; 47:1473-1482.
25. Sheldon J, Camino N, Rodés B, et al. Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. Antivir Ther 2005; 10:727-734.
26. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naïve patients with hepatitis B. Hepatology 2006; 44:1656-1665.
27. Tenney DJ, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine. Antimicrob Agents Chemother 2004; 48:3498-3507.
28. Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS 2002; 16:131-133.
29. Yim HJ, Hussain M, Liu Y, Wong SN, Fung SK, Lok ASF. Evolution of multi-drug resistant hepatitis B virus during sequential therapy. Hepatology 2006; 44:703-712.
30. Lee YS, Chung YH, Kim JA, et al. Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy. Liver Int 2009; 29:552-556.
31. Warner N, Locarnini S, Kuiper M, et al. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 2007; 51:2285-2292. (Pubitemid 47047302)
32. Seifer M, Patty A, Serra I, Li B, Standring DN. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir. Antiviral Res 2009; 81:147-155.
33. Tenney DJ, Rose RE, Baldick CJ, et al. Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51:902-911.